Robots for this group tickers :
Swing Trader for Beginners: Trading in Markets Trending Down (TA&FA) - 30-day Annualized Return +50%
Swing Trader for Beginners: Trading in Markets Trending Up (TA&FA) - 30-day Annualized Return +24%
The biopharmaceutical sector, specifically focusing on plastic surgery, has been a dynamic landscape, marked by notable performances and intriguing market dynamics. In the past month, companies within this niche have seen a robust +14.87% increase in performance, capturing the attention of investors. However, a closer look at key indicators and individual tickers reveals a nuanced picture.
Negative Outlook Backed by Indicators
Tickeron's Negative Outlook: The Negative Outlook today is substantiated by Tickeron's 15 Indicator Stock Fear & Greed Index. This Index, reflecting market sentiment, suggests caution in the current environment. Tickeron predicts a further decline of over 4.00% within the next month, with a 70% likelihood. The daily ratio of advancing to declining volumes over the past month was 1.61 to 1, indicating a potential shift in momentum.
TrendWeek Indicator: Two stocks within this sector exhibit a negative trend, as indicated by the TrendWeek indicator, with an average likelihood of 68%. This trend analysis underscores the cautionary sentiment surrounding these stocks.
Market Cap Overview
Diverse Valuations: The average market capitalization across the group stands at 13B, showcasing the diversity within the sector. Notably, Zimmer Biomet Holdings (ZBH) holds the highest valuation at 23.8B, while CYCCP is valued at the lower end with a market cap of 0.
Highs and Lows in Price Movements
Weekly, Monthly, and Quarterly Trends: The average weekly price growth for the group is a notable 3%, while the monthly and quarterly trends stand at 14.87% and 13.45%, respectively. These figures provide insight into the dynamic nature of the sector. CYCCP experienced the highest price growth at 16.36%, while ALKS faced a significant fall of -4.21%.
Stock-Specific News: Recent price movements for Zimmer Biomet Holdings (ZBH) showcase the volatility within the sector. The stock gained +5.38% in a week but also saw a notable decline of -9.48% in another, highlighting the inherent unpredictability.
Volume Insights
Fluctuating Volumes: While the average weekly volume growth stands at 25.77%, the monthly and quarterly trends indicate a decline of -42.49% and -0.77%, respectively. Notably, Alkermes witnessed a record-breaking daily growth of 368% of the 65-Day Volume Moving Average, indicating an unusual surge in interest.
Individual Stock Analysis
NBIX: Signs of Downtrend:
ALKS: RSI Oscillator Shift:
ZBH: Uptrend Continuation:
Summary:
In summary, while the overall sector has shown positive growth, caution is warranted due to the Negative Outlook from Tickeron and concerning trends in individual stocks. Investors should carefully evaluate risk tolerance and consider the specific indicators mentioned to make informed decisions in this dynamic biopharmaceutical landscape.
The 10-day moving average for NBIX crossed bullishly above the 50-day moving average on May 01, 2024. This indicates that the trend has shifted higher and could be considered a buy signal. In of 13 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are .
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where NBIX's RSI Indicator exited the oversold zone, of 29 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. of 58 cases where NBIX's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .
The Moving Average Convergence Divergence (MACD) for NBIX just turned positive on May 15, 2024. Looking at past instances where NBIX's MACD turned positive, the stock continued to rise in of 48 cases over the following month. The odds of a continued upward trend are .
NBIX moved above its 50-day moving average on May 14, 2024 date and that indicates a change from a downward trend to an upward trend.
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where NBIX advanced for three days, in of 303 cases, the price rose further within the following month. The odds of a continued upward trend are .
The Momentum Indicator moved below the 0 level on May 15, 2024. You may want to consider selling the stock, shorting the stock, or exploring put options on NBIX as a result. In of 87 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .
Following a 3-day decline, the stock is projected to fall further. Considering past instances where NBIX declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
NBIX broke above its upper Bollinger Band on May 01, 2024. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for NBIX entered a downward trend on April 29, 2024. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock better than average.
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. NBIX’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (6.297) is normal, around the industry mean (49.922). P/E Ratio (57.202) is within average values for comparable stocks, (83.825). Projected Growth (PEG Ratio) (0.464) is also within normal values, averaging (2.825). Dividend Yield (0.000) settles around the average of (0.115) among similar stocks. P/S Ratio (7.564) is also within normal values, averaging (62.804).
The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
a product based biopharmaceutical company
Industry PharmaceuticalsOther